MedTrace Logo

Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.

NCT00244127 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2005-10-28

No results posted yet for this study

Summary

To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the R-CHOP regimen.

Conditions

  • Aggressive Non-Hodgkin's Lymphoma in the Elderly.

Interventions

DRUG

Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)

Sponsors & Collaborators

  • Zeneus Pharma

    lead INDUSTRY

Principal Investigators

  • Massimo Federico · Universita Degli Studi di Modena

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31

Countries

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00244127 on ClinicalTrials.gov